Drug | Target | FDA approval for JIA | Route | Dosage options |
---|---|---|---|---|
Etanercept (Enbrel) | TNFα | Polyarticular JIA ages 2 years and older | Subcutaneous injection | 0.8 mg/kg/dose once a week, maximum 50 mg/dose |
Infliximab (Remicade) | TNFα | No | Intravenous infusion | 6 to 10 mg/kg/dose weeks 0, 2 and 6; then every 4 to 8 weeks |
Adalimumab (Humira) | TNFα | Polyarticular JIA ages 4 years and older | Subcutaneous injection | 24 mg/m2 every 2 weeks, maximum 40 mg/dose |
Anakinra (Kineret) | IL-1 | No | Subcutaneous injection | 1 to 2 mg/kg/day, maximum 100 mg/dose |
Rilonacept (IL-1 Trap) | IL-1 | No | Subcutaneous injection | 2.2 to 4.4 mg/kg once a week |
Abatacept (Orencia) | Cytotoxic T-lymphocyte- associated antigen 4 | Polyarticular JIA ages 6 years and older | Intravenous infusion | 10 mg/kg weeks 0, 2 and 4; then every 4 weeks, maximum 1,000 mg/dose |
Rituximab (Rituxan) | CD20 | No | Intravenous infusion | 750 mg/m2; two doses 2 weeks apart or 375 mg/m2; four doses, weekly × 4, maximum 1,000 mg/dose |
Tocilizumab (MRA) | IL-6 | No | Intravenous infusion | 8 to 12 mg/kg every 2 weeks |